设为首页 加入收藏

TOP

新型化疗止吐剂VARUBI IV获FDA批准上市(二)
2017-11-17 03:49:26 来源: 作者: 【 】 浏览:1487次 评论:0
Precautions:
Consider interactions with CYP2D6 substrates before starting treatment. Avoid in severe hepatic impairment; monitor if use cannot be avoided. Pregnancy. Nursing mothers.
Interactions:
See Contraindications. Potentiates CYP2D6 substrates (eg, dextromethorphan) and possibly others; see full labeling. Antagonized by strong CYP3A4 inducers (eg, rifampin); avoid. Tabs: potentiates BCRP substrates (eg, methotrexate, topotecan, irinotecan) and P-gp substrates (eg, digoxin) with narrow therapeutic index; monitor if use cannot be avoided. Use lowest effective dose of rosuvastatin (see drug's full labeling for dosing). Monitor INR and PT with concomitant warfarin; adjust dose as needed.
Pharmacological Class:
Substance P/NK1 receptor antagonist.
Adverse Reactions:
Neutropenia, hiccups, abdominal pain, decreased appetite, dizziness, dyspepsia, UTI, stomatitis, anemia.
Generic Availability:
NO
How Supplied:
Single dose pack—1 (2 x 90mg tabs) 

Tags: 责任编辑:admin
首页 上一页 1 2 下一页 尾页 2/2/2
】【打印繁体】【投稿】【收藏】 【推荐】【举报】【评论】 【关闭】 【返回顶部
分享到QQ空间
分享到: 
上一篇默沙东抗病毒药物Prevymis获美国F.. 下一篇新化疗止吐新药VARUBI获FDA批准,..

相关栏目

最新文章

图片主题

热门文章

推荐文章

相关文章

广告位